臺積電(TSM.US)首季利潤按年增45.1%至2,027億新臺幣
臺積電(TSM.US)公佈年第一季財務報告,合併營收約4,910.8億元新臺幣(下同),按年增35.5%,按季升12.1%;稅後純益約2,027.3億元,按年上升45.1%,按季則增22%,每股盈餘爲7.82元。
若以美金計算,今年第一季營收爲175.7億美元,按年增加36%,按季則升11.6%。
今年第一季,毛利率爲55.6%,營業利益率爲45.6%,稅後純益率則爲41.3%。
集團指,5納米制程出貨佔臺積公司今年第一季晶圓銷售金額的20%;7納米制程出貨佔全季晶圓銷售金額的30%。總體而言,先進製程(包含7納米及更先進製程)的營收達到全季晶圓銷售金額的50%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.